WO2017111129A1 - Nouvelle anomalie génétique liée à la leucémie aiguë lymphoblastique et son utilisation - Google Patents

Nouvelle anomalie génétique liée à la leucémie aiguë lymphoblastique et son utilisation Download PDF

Info

Publication number
WO2017111129A1
WO2017111129A1 PCT/JP2016/088570 JP2016088570W WO2017111129A1 WO 2017111129 A1 WO2017111129 A1 WO 2017111129A1 JP 2016088570 W JP2016088570 W JP 2016088570W WO 2017111129 A1 WO2017111129 A1 WO 2017111129A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
bcl9
mef2d
fusion
exon
Prior art date
Application number
PCT/JP2016/088570
Other languages
English (en)
Japanese (ja)
Inventor
友介 奥野
勢二 小島
喬悟 鈴木
希 川島
由子 関屋
Original Assignee
国立大学法人名古屋大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人名古屋大学 filed Critical 国立大学法人名古屋大学
Priority to JP2017558310A priority Critical patent/JPWO2017111129A1/ja
Publication of WO2017111129A1 publication Critical patent/WO2017111129A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Definitions

  • the present invention relates to a novel genetic abnormality related to acute lymphoblastic leukemia. Specifically, it relates to various uses (for example, testing method, determination of treatment policy, treatment method) of the newly found MEF2D-BCL9 fusion gene.
  • This application claims priority based on Japanese Patent Application No. 2015-255179 filed on Dec. 25, 2015, the entire contents of which are incorporated by reference.
  • ALL Acute lymphoblastic leukemia
  • Japan 500 cases occur annually, and the long-term survival rate is around 80%.
  • ALL it is known that it develops with various genetic abnormalities (gene fusion, gene deletion / amplification, point mutation) (Non-patent Document 1).
  • Gene fusion, gene deletion / amplification, point mutation gene fusion, gene deletion / amplification, point mutation
  • Non-patent Document 1 Acute lymphoblastic leukemia
  • ALL having an ETV6-RUNX1 fusion gene or a TCF3-PBX1 fusion gene responds well to normal chemotherapy and has a good prognosis.
  • ALL with the BCR-ABL fusion gene was considered to have a poor prognosis, but it became clear that treatment with BCR-ABL molecular target drugs (imatinib, dasatinib, etc.) improved the prognosis.
  • ALL with point mutations / deletions in the TP53 and IKZF1 genes and ALL with partial amplification within chromosome 21 have a poor prognosis.
  • ALL having a point mutation in the NT5C2 gene has resistance to a specific chemotherapy (6-mercaptopurine) (Patent Document 1).
  • Recent large-scale studies have identified a group of ALL with activated thyrone kinase mutations (due to point mutations and gene fusions) and suggested the possibility of treatment with corresponding thyrone kinase inhibitors.
  • ALL Although various genetic abnormalities have been discovered in ALL, there is still an example (B-other ALL) in which no genetic abnormality that predicts prognosis is found.
  • B-other ALL Another hypothesis explaining this may be that the genetic abnormality in ALL is still insufficiently elucidated. For example, there are many reports of analysis at the time of diagnosis, but there are few reports of analysis at a more advanced stage such as the time of recurrence.
  • the long-term survival rate of ALL patients is improving to 90%, but in order to further improve treatment outcomes, new genetic abnormalities and molecules that predict response to specific chemotherapy It may be necessary to look for genetic abnormalities that are the target of targeted therapy.
  • an object of the present invention is to meet such needs and contribute to the improvement of ALL treatment results.
  • MEF2D-BCL9 fusion gene alone defines a group of characteristic ALL. Therefore, if the presence of a genetic abnormality characterized by the formation of the fusion gene is used as an index, it can be said that the case can be identified and a more effective treatment policy can be determined.
  • MEF2D gene fusion with DAZAP1 gene (Patent Document 2, Non-Patent Documents 2 and 3) and fusion with CSF1R gene (Non-Patent Document 4) have been reported.
  • HDAC9 is a class IIa histone deacetylase and is involved in transcriptional regulation.
  • drugs effective for inhibiting HDAC9 HDAC inhibitors such as vorionstat, quisinostat and TMP269 have been developed.
  • a drug susceptibility test using patient-derived primary cultured leukemia cells was performed.
  • HDAC inhibitors (vorinostat, xinostat) showed significant cell growth inhibitory activity.
  • bortezomib a proteasome inhibitor that is expected to be effective against treatment-resistant B-precursor ALL, showed similar activity. That is, the possibility that the HDAC inhibitor and the proteasome inhibitor are effective for the treatment of the case was shown.
  • the following invention is mainly based on the above-mentioned results.
  • a method for testing acute lymphocytic leukemia comprising the following steps (1) to (3): (1) preparing a specimen containing leukemia cells isolated from a patient with acute lymphoblastic leukemia; (2) detecting the presence or absence of a fusion gene of the MEF2D gene and the BCL9 gene or a fusion protein encoded by the fusion gene in the specimen; (3) A step of determining that the prognosis is poor or difficult to treat when the fusion gene or the fusion protein is detected.
  • Method. [3] The detection of the fusion gene in step (2) is from the group consisting of RT-PCR, PCR, PCR-RFLP, PCR-SSCP, RNA sequence analysis, target sequence analysis, FISH method and whole genome analysis.
  • [4] The examination method according to any one of [1] to [3], wherein the patient with acute lymphoblastic leukemia is a child.
  • the therapeutic policy determined or changed in the step (4) or (4 ′) includes treatment by administration of a histone deacetylase inhibitor and / or a proteasome inhibitor, [5] or [ 6].
  • the examination method according to [5] or [6], wherein the treatment policy determined or changed in step (4) or (4 ′) includes adaptation of hematopoietic stem cell transplantation.
  • Treatment of acute lymphocytic leukemia comprising treating the patient with acute lymphocytic leukemia according to a treatment policy determined or changed by the test method according to any one of [5] to [11] Method.
  • a medicament for treating a patient with acute lymphocytic leukemia characterized by formation of a fusion gene of MEF2D gene and BCL9 gene, comprising a histone deacetylase inhibitor and / or a proteasome inhibitor.
  • the medicament according to [13], wherein the histone deacetylase inhibitor is a histone deacetylase 9 inhibitor.
  • a therapeutically effective amount of a medicine containing a histone deacetylase inhibitor and / or a proteasome inhibitor is administered to a patient with acute lymphocytic leukemia characterized by the formation of a fusion gene between the MEF2D gene and the BCL9 gene A method for treating acute lymphoblastic leukemia.
  • the histone deacetylase inhibitor is a histone deacetylase 9 inhibitor.
  • a kit for detecting a genetic abnormality characterized by formation of a fusion gene of a MEF2D gene and a BCL9 gene comprising the primer set according to [17] or [18].
  • a screening method for a substance effective for the treatment of a patient with acute lymphocytic leukemia characterized by formation of a fusion gene of MEF2D gene and BCL9 gene comprising the following steps (i) to (iii): (i) providing a cell expressing a fusion gene of MEF2D gene and BCL9 gene; (ii) culturing the cell in the presence of a test substance; (iii) measuring the number of viable cells and determining the effectiveness of the test substance. [24] A fusion gene of MEF2D gene and BCL9 gene.
  • [25] The fusion gene according to [24], which is generated by chromosomal inversion in which a breakpoint exists in intron 6 or 7 in the MEF2D gene and a breakpoint exists in exon 8 or intron 9 in the BCL9 gene.
  • the fusion gene according to [25] comprising exons 1 to 6 of the MEF2D gene and exon 10 of the BCL9 gene or a part thereof.
  • the fusion gene according to [26] comprising the sequence of SEQ ID NO: 11 and the sequence of SEQ ID NO: 12.
  • [29] The fusion protein according to [28], comprising the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 14. [30] DNA complementary to mRNA that is a transcription product of the fusion gene according to any one of [24] to [27]. [31] The DNA of [30], comprising the sequence of SEQ ID NO: 15 and the sequence of SEQ ID NO: 16. [32] An antibody that recognizes a fusion protein encoded by a fusion gene of MEF2D gene and BCL9 gene. [33] The antibody according to [32], wherein the fusion protein is a fusion protein defined in [28] or [29].
  • A The position on the chromosome of MEF2D gene and BCL9 gene.
  • B An example of a breakpoint that forms a fusion gene of MEF2D-BCL9. Detection of fusion gene mRNA by RT-PCR. RT-PCR results. Case 1 (upper) and case 4 (lower) are shown. Detection of breakpoints in genomic DNA. PCR results (top). Detection was attempted using primer set 4 (left) and primer set 5 (right). The genomic breakpoints in each case are shown in the bottom row. Results of expression profile analysis. Functional analysis of MEF2D-BCL9 fusion gene.
  • HDAC9 expression levels were compared between MEF2D-BCL9 positive and negative cases (A).
  • MELM2D-BCL9 was introduced into NALM-6, and the expression level (B) and cell proliferation rate (C) of HDAC9 were examined.
  • Effect of molecular target drugs Using primary culture cells established from patient leukemia cells positive for MEF2D-BCL9 fusion gene, the effect (drug sensitivity) of vorinostat (A), xynostat (B), and bortezomib (C) was tested.
  • the first aspect of the present invention relates to a test method for ALL.
  • the following steps (1) to (3) are performed.
  • step (1) prepare a sample to be used for the test.
  • Specimens containing leukemia cells isolated from ALL patients are used.
  • the type and origin of the specimen are not particularly limited.
  • a cell fraction (bone marrow cell) prepared from bone marrow or a cell fraction (blood cell) prepared from blood such as peripheral blood is used as a specimen.
  • the test method of the present invention is particularly useful for predicting the prognosis of ALL in children, determining the treatment policy, and the like, it is preferable to use a sample derived from a child with ALL. In general, children under the age of 15 are considered children.
  • the specimen is prepared prior to the practice of the present invention. That is, the examination method of the present invention does not include a step of isolating (collecting) bone marrow or the like for preparing a specimen from a patient.
  • step (2) the presence or absence of a fusion gene (MEF2D-BCL9 fusion gene) of MEF2D gene and BCL9 gene or a fusion protein encoded by the fusion gene is detected in the sample.
  • a fusion gene (MEF2D-BCL9 fusion gene is detected)
  • genomic DNA or mRNA is the detection target.
  • genomic DNA is targeted for detection
  • the presence or absence of fusion gene formation due to partial inversion of the chromosome is detected.
  • mRNA is the detection target, the presence or absence of the expression of the fusion gene is detected.
  • the means for detecting the MEF2D-BCL9 fusion gene is not particularly limited.
  • RT-PCR reverse transcription-polymerase chain reaction
  • PCR method PCR method
  • PCR-RFLP restriction fragment fragment length polymorphism
  • PCR-SSCP single strand strand conformation polymorphism
  • RNA sequence analysis target sequence analysis
  • FISH Fluorescence in situ hybridization
  • Invader registered trademark, Third Wave Technologies
  • LAMP Loop-Mediated Isothermal Amplification
  • CGH Comparative Genomic Hybridization
  • dot hybridization method Northern hybridization method, etc.
  • the detection means can be used. Extraction and purification of genomic DNA and mRNA can be performed by known methods. Various kits for preparation are commercially available, and they may be used.
  • the MEF2D-BCL9 fusion gene is a novel fusion gene derived from ALL patients, as shown in the Examples below. According to the study by the present inventors, it is clear that the fusion gene is formed by a chromosomal inversion in which a breakpoint exists in intron 6 or 7 in the MEF2D gene and a breakpoint exists in exon 8 or intron 9 in the BCL9 gene. It became. Based on this information, it is possible to design and prepare primers and probes used for detection of fusion genes. Specific examples of primers that can be used in detection means using the nucleic acid amplification reaction (the above-mentioned RT-PCR method and PCR method) will be described later.
  • the fusion protein can be detected by an immunological assay.
  • an antibody against the fusion protein is used, and the fusion protein is detected using the binding property (binding amount) of the antibody as an index.
  • immunoassays are Western blot, immunohistochemistry, fluorescence immunoassay (FIA), enzyme immunoassay (EIA), radioimmunoassay (RIA), flow cytometry (FCM) , Immunoprecipitation, immunochromatography, ELISA, and the like.
  • step (3) the prognosis or treatment difficulty of the patient is evaluated based on the detection result in step (2). Specifically, when a fusion gene or fusion protein to be detected in step (2) is detected, it is determined that the prognosis is poor or treatment is difficult.
  • genetic abnormalities characterized by the formation of the MEF2D-BCL9 fusion gene (hereinafter referred to as “genetic abnormalities of the present invention”) are used as indicators for determining the prognosis and treatment responsiveness of ALL patients. May be used). The determination here can be automatically / mechanically performed without depending on the determination of a person having specialized knowledge such as a doctor or a laboratory technician, as is apparent from the determination criteria.
  • step (4) is performed following step (3). (4) Based on the determination in step (3), identifying a risk group to which the patient with acute lymphocytic leukemia belongs, and determining or changing a treatment policy
  • ALL stratification treatment In ALL, stratified treatment is generally performed according to risk.
  • ALL stratification treatment generally consists of remission induction therapy, intensive therapy, central nervous system invasion prevention therapy, remission induction therapy, maintenance therapy, etc., and a treatment policy combining these therapies is set. Indications for hematopoietic stem cell transplantation are also considered when treatment alone is not possible with chemotherapy.
  • Treatment of ALL usually begins with the initial goal of introducing remission. After successful introduction of remission, treatment is performed to further reduce the remaining tumor cells while preventing infiltration of the central nervous system and the like. Thereafter, maintenance therapy, re-induction therapy, etc. will be continued, aiming to eradicate tumor cells.
  • stratified treatment of ALL multiple risk groups are set using various indicators, and treatment is performed for each risk group according to the optimal treatment policy.
  • a risk group to which a patient should belong is identified based on examinations before and after the start of treatment. The therapeutic effect is maximized by the stratified treatment.
  • the inspection method of the present invention is performed before or after the start of treatment. If it is carried out before the start of treatment, the present invention can be used to identify a provisional or definite risk group (to which an immediate or definitive treatment policy is determined).
  • Stratified treatment protocols include, for example, age, white blood cell count, chromosomal / gene abnormalities, initial treatment (eg, methotrexate (MTX) intrathecal injection and 7-day prednisolone (PSL) administration), presence or absence of central nervous system invasion, etc.
  • test method of the present invention is carried out before the start of treatment and the results are used, cases having genetic abnormalities of the present invention can be classified into more qualified risk groups, and earlier and appropriate treatment can be performed. It becomes possible.
  • the test method of the present invention is carried out after the start of treatment, the present invention can be used for determination or change of risk groups (accordingly, subsequent treatment policy is determined). This aspect allows, for example, a review of the treatment policy if it recurs after remission.
  • the examination method of the present invention may be performed multiple times over time to monitor the treatment effect and review the treatment policy (for example, change of risk group and change of treatment method associated therewith).
  • Step (4) corresponds to stratification using the genetic abnormality of the present invention as an index.
  • the “risk group” identified in step (4) is typically a group associated with a high risk, that is, a “high risk group”.
  • a corresponding risk group can be identified from among a plurality of risk groups set in the stratified treatment protocol. Below, a specific example is shown regarding this point.
  • JACLS Choildren's Leukemia Research Group
  • TCCSG Tokyo Children's Cancer Research Group
  • CCLSG Cho Children's Cancer and Leukemia Research Group
  • KYCCSG Knowu / Yamaguchi Children's Cancer Research Group
  • the standard risk group (SR group) and the intermediate risk group
  • the present invention is applied to this protocol, for example, at the time of determination of poor prognosis or difficult treatment (step (3)), the patient is considered to belong to the “HR group” and another determination (ie, step ( When the fusion gene or fusion protein of the MEF2D gene and the BCL9 gene is not detected in 2), the patient belongs to the “SR group” or the patient belongs to the “IR group”.
  • the patient belongs to the “ER group” and another determination (ie, When the fusion gene or fusion protein of MEF2D gene and BCL9 gene is not detected in step (2)), it is assumed that the patient belongs to the “HR group” or the patient belongs to the “SR group”.
  • patients in whom the genetic abnormality of the present invention is detected are usually classified into high risk groups (poor prognosis, difficult treatment) among a plurality of set risk groups.
  • high risk groups poor prognosis, difficult treatment
  • step (4) and alternative step (4 ') the risk group to which the patient belongs is specified by using the determination in step (3) and the results of other tests together.
  • various indices including a new index provided by the present application that is, the genetic abnormality of the present invention are comprehensively evaluated to identify a risk group to which the patient belongs.
  • tests here include interviews, physical examination (extramedullary invasion, especially testicular invasion screening, etc.), blood tests (total blood count, blood biochemistry, cell surface marker analysis, detection of chromosomal abnormalities), Imaging (chest x-ray (eg, mediastinal mass screening)), ultrasonography, CT examination, bone marrow puncture or bone marrow biopsy (nucleated cell count, May Giemsa staining, peroxidase staining, esterase staining, cell surface Marker analysis, detection of chromosomal abnormalities, G-band staining, genetic analysis, pathological examination), cerebrospinal fluid examination, and the like. These inspections may be performed in a conventional manner. In addition, contract inspection may be used. For example, BML Inc., SRL Inc., etc. provide contract inspection services for the detection of chromosomal abnormalities, which is one of the most important tests for appropriate stratified therapy.
  • a dedicated risk group is provided, and in step (4) or (4 '), the fusion gene or fusion protein of the MEF2D gene and the BCL9 gene is The detected patient may belong to the risk group.
  • treatment policy is set for each risk group. Therefore, by specifying the risk group to which the patient belongs, the patient's treatment policy is also determined.
  • step (4) or (4 The risk group identified in ') may differ from the previous risk group (ie, the risk group is changed).
  • the treatment policy is also changed with the change of the risk group.
  • the treatment strategy after the change typically includes an enhanced therapy than before the change.
  • Intensified therapy for example, increased the number of drugs used in combination (for example, use of etoposide, ifosfamide, vindesine in high-risk groups), increased cumulative doses / number of doses of drugs (eg, vincristine, daunorubicin, Intrathecal injection of cyclophosphamide, L-asparaginase, methotrexate, cytarabine, methotrexate, cytarabine and prednisolone) chemotherapy, cranial radiation, or hematopoietic stem cell transplantation.
  • drugs eg, vincristine, daunorubicin, Intrathecal injection of cyclophosphamide, L-asparaginase, methotrexate, cytarabine, methotrexate, cytarabine and prednisolone
  • the treatment policy determined in step (4) or (4 ′) (also applicable to the modified treatment policy) is a histone deacetylase inhibitor or proteasome inhibitor, or Treatment by administration of both of these is included.
  • cases of genetic abnormalities according to the present invention have a poor prognosis and show resistance to treatment, and therefore, more aggressive and enhanced treatment application is desired.
  • the treatment policy determined in step (4) or (4 ′) (also applicable to the modified treatment policy) includes indication of hematopoietic stem cell transplantation.
  • hematopoietic stem cell transplantation is used when chemotherapy alone cannot be cured. Hematopoietic stem cell transplantation is performed during the first remission phase or a subsequent remission phase, but is preferably the first remission phase so as to enhance the therapeutic effect by early aggressive therapeutic intervention.
  • hematopoietic stem cell transplantation are allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood stem cell transplantation, and mini-transplantation.
  • allogeneic bone marrow transplantation has few recurrences of disease, it has the problem that there are many complications (for example, GVHD) accompanying transplantation.
  • Peripheral blood stem cell transplantation is a method in which hematopoietic stem cells in peripheral blood are collected and transplanted, and has an advantage that hematopoietic recovery after transplantation is quick.
  • Umbilical cord blood stem cell transplantation has advantages such as no burden on the donor and early transplantation.
  • Mini-transplantation is a method for reducing side effects by reducing the amount of pre-transplantation treatment (administration of anticancer drugs or irradiation) by using an immunosuppressant, and is also called non-myeloablative transplantation.
  • the test method of the present invention is useful for determining, changing, and reviewing the ALL treatment policy.
  • ALL can be treated under a more optimized treatment policy.
  • this invention provides the treatment method using the test
  • prevention, remission, prevention or cure of an illness (ALL) or a disease state is intended.
  • Treatment after symptoms appear is aimed at reducing, ameliorating or eliminating the symptoms and / or related symptoms, or preventing exacerbations.
  • Treatment before symptoms appear typically aims to reduce the risk of symptoms appearing or to reduce the severity if symptoms appear.
  • an acute lymphoblastic leukemia patient is treated according to the treatment policy determined or changed by the test method of the present invention.
  • more optimized stratification treatment is possible.
  • Specific examples of treatment in the therapeutic method of the present invention are chemotherapy, hematopoietic stem cell transplantation, and radiation therapy. If classified according to purpose, remission induction therapy, reinforcement therapy, central nervous system invasion prevention therapy, remission induction therapy, maintenance therapy and the like can be mentioned.
  • drugs used in chemotherapy include corticosteroids (prednisolone, dexamethasone, hydrocortisone), alkylating agents (eg cyclophosphamide, ifosfamide, melphalan), antimetabolites (eg methotrexate, 6-mercapto) Purine, cytarabine, fludarabine, clofarabine), anticancer antibiotics (eg, daunorubicin, doxorubicin, pirarubicin, idarubicin, mitoxantrone), plant alkaloids (eg, vincristine, vinblastine, vindesine, etoposide), L-asparaginase.
  • corticosteroids prednisolone, dexamethasone, hydrocortisone
  • alkylating agents eg cyclophosphamide, ifosfamide, melphalan
  • antimetabolites eg methotrexate, 6-mercapto
  • Chemotherapy is based on multi-drug combination therapy that combines several types of anticancer drugs with different mechanisms of action and side effects.
  • Drug administration methods include intravenous injection (one-shot intravenous injection method, intravenous infusion method), subcutaneous injection, intramuscular injection, oral administration (internal use), intrathecal injection and the like.
  • the present invention is further based on the fact that histone deacetylase (HDAC) inhibitors and proteasome inhibitors have been suggested to be effective for cases in which the genetic abnormality of the present invention is observed, and specific cases of ALL Provide medicines for
  • the medicament of the present invention is used for the treatment of ALL patients with a genetic abnormality characterized by the formation of the MEF2D-BCL9 fusion gene, and contains an HDAC inhibitor, a proteasome inhibitor, or both as active ingredients .
  • the HDAC inhibitor and the proteasome inhibitor are not particularly limited.
  • As the HDAC inhibitor preferably, one that inhibits HDAC9 directly or through other molecules is employed.
  • HDAC inhibitors examples include vorinostat, panobunostat, quisinostat, romidepsin, TMP269 (see Baas, T. Closer to class IIa HDAC inhibitors. SciBX 6 (13) 2013) .
  • Vorinostat is a class I and class II HDAC inhibitor and is marketed under the trade name “ZOLINZA®”.
  • Romidepsin is a class I HDAC inhibitor and is marketed under the trade name “ISTODAX (registered trademark)”.
  • proteasome inhibitors are bortezomib, carfilzomib, ixazomib. Bortezomib is a drug that is expected to have an effect on treatment-resistant B-precursor ALL in recent years.
  • Treatment with a therapeutically effective amount of the medicament of the present invention can be expected as a promising therapeutic strategy for ALL patients with genetic abnormalities of the present invention.
  • Primer set and detection kit for detecting a novel genetic abnormality A further aspect of the present invention provides a primer set and a detection kit for detecting a genetic abnormality of the present invention.
  • the primer set of the present invention is typically used in the inspection method of the present invention. The same applies to the detection kit.
  • the MEF2D gene and the BCL9 are formed by a chromosomal inversion in which a breakpoint exists in intron 6 or 7 in the MEF2D gene and a breakpoint exists in exon 8 or intron 9 in the BCL9 gene. It is designed to specifically amplify DNA (cDNA) complementary to mRNA which is a fusion gene with a gene or its transcription product.
  • cDNA DNA
  • Examples of the primer set of the present invention include the following.
  • a forward primer consisting of a sequence complementary to a part of exon 1 to 6 of the MEF2D gene and consisting of 13 bases or more, and a part of the exon 10 region of the BCL9 gene consisting of 13 bases or more
  • Primer set consisting of reverse primers consisting of complementary sequences
  • primer sets targeting cDNA include the following (a1) to (a3). Since the primer set targets cDNA, it is suitable for various methods such as RT-PCR, in which cDNA prepared using mRNA as a template is to be detected.
  • (a1) Forward primer consisting of a sequence complementary to a part of the exon 3 to 4 region of the MEF2D gene and 13 bases or more, and a part of the exon 10 region of the BCL9 gene from 13 bases or more
  • BCL9 Primer set consisting of a reverse primer consisting of a sequence complementary to a part of the exon 10 region of the gene that is complementary to a part consisting of 13 bases or more
  • a part of the region of the exon 6 of the MEF2D gene consist
  • primer set (a1) examples include a forward primer 5′-CATCATCGAGACCCTGAGGAAG-3 ′ (SEQ ID NO: 1) and reverse primer 5′-TGTGGGGGAGACTGTACTGG-3 ′ (SEQ ID NO: 2). .
  • a set of forward primer 5′-GGCGCTATGGGTCAACTGTC-3 ′ (SEQ ID NO: 3) and reverse primer 5′-CGTCCTTGAGGTACCATCGG-3 ′ (SEQ ID NO: 4) is Specific examples of the primer set of a3) include a set of forward primer 5′-GCCCGTGTCCAATCAGAGC-3 ′ (SEQ ID NO: 5) and reverse primer 5′-CCGGGCATTGTAGATTGTGC-3 ′ (SEQ ID NO: 6).
  • primer set targets genomic DNA, and the MEF2D gene has a breakpoint in intron 6 or 7 and the BCL9 gene has a breakpoint in exon 8 or intron 9.
  • MEF2D gene has a breakpoint in intron 6 or 7
  • BCL9 gene has a breakpoint in exon 8 or intron 9.
  • Preferable specific examples include the following (b1) and (b2). These primer sets are suitable for PCR, but are not limited to use in other nucleic acid amplification reactions.
  • (b1) A part of the exon 2 region of the MEF2D gene that is complementary to a portion consisting of 13 bases or more and a part of the exon 10 region of the BCL9 gene that is a portion of 13 bases or more
  • B2 A forward primer consisting of a sequence complementary to a part of the exon 5 region of the MEF2D gene that is complementary to a part consisting of 13 or more bases
  • exon 10 of the BCL9 gene Primer set consisting of a reverse primer consisting of a sequence complementary to a part of the region of 13 and more than 13 bases
  • primer set (b1) examples include a forward primer 5′-AGGCTGTGCAGAAGGTATCC-3 ′ (SEQ ID NO: 7) and reverse primer 5′-GTGCAACACATGACCGATGG-3 ′ (SEQ ID NO: 8).
  • primer set (b2) a set of forward primer 5′-TTCTGTGGGCCAGAAATGGA-3 ′ (SEQ ID NO: 9) and reverse primer 5′-GGGACCCCATGAGGAGGTAT-3 ′ (SEQ ID NO: 10) can be mentioned. it can.
  • the length of each primer is usually 13 bases or more (upper limit is, for example, 40 bases), but preferably 15 bases to 30 bases, more preferably 18 bases to 26 bases in consideration of specificity, efficiency of amplification reaction, and the like.
  • the base is more preferably 20 to 24 bases.
  • the length of the DNA fragment amplified by the primer set is, for example, 200 to 2000 bases long, preferably 400 to 1500 bases long when cDNA is a target, and 500 to 500 bases long when genomic DNA is a target.
  • the length is 12000 bases, preferably 800 to 10000 bases.
  • Each primer sequence is complementary to the target (template) sequence, but only slightly between the primer sequence and the target sequence as long as specific hybridization occurs and the desired DNA fragment is specifically amplified. There may be minor mismatches.
  • the degree of mismatch is 1 to several, preferably 1 to 3, and more preferably 1 to 2.
  • the primer can be previously labeled with a labeling substance.
  • a labeled primer for example, detection using the labeling amount of the amplification product as an index becomes possible.
  • 7-AAD Alexa Fluor (registered trademark) 488, Alexa Fluor (registered trademark) 350, Alexa Fluor (registered trademark) 546, Alexa Fluor (registered trademark) 555, Alexa Fluor (registered) trademark) 568, Alexa Fluor (registered trademark) 594, Alexa Fluor (registered trademark) 633, Alexa Fluor (registered trademark) 647, Cy TM 2, DsRED , EGFP, EYFP, FITC, PerCP TM, R-Phycoerythrin, Propidium Iodide, AMCA, DAPI, ECFP, MethylCoumarin, Allophycocyanin (APC), Cy TM 3, Cy TM 5, Rhodamine-123, Tetramethylrhodamine, Texas Red (Tex
  • primer design software examples include Primer 3, OLIGO Primer Analysis Software, Primer-BLAST, and the like.
  • the primer can be synthesized by a known method such as a phosphodiester method.
  • the kit of the present invention makes it possible to perform the detection method of the present invention simply and efficiently.
  • the detection kit of the present invention contains the primer set of the present invention as an essential element.
  • the primer set (a) and the primer set (b) are preferably included.
  • the detection kit targeting genomic DNA preferably includes the primer set (A) and the primer set (B). According to these detection kits, the coverage of cases of genetic abnormalities according to the present invention (that is, the number of cases detected as having genetic abnormalities) is increased, and the test results are more useful. .
  • the kit of the present invention may contain other elements. Examples of other elements are instructions on the use of primer sets, various reagents (DNA polymerase, restriction enzymes, buffers, etc.), solvents, standard specimens, reaction vessels, and other instruments. Further, it may include guidelines and explanations for determining a treatment policy.
  • Drug screening method The present invention further shows that ALL cells introduced with the MEF2D-BCL9 fusion gene expressed HDAC9 as well as MEF2D-BCL9-positive patient-derived cells and increased their proliferation rate (Examples described later). And the fact that a drug susceptibility evaluation system could be constructed using MEF2D-BCL9 positive patient-derived cells (see the Example section below), the fusion gene of MEF2D gene and BCL9 gene Provided is a screening method for substances effective in the treatment of patients with ALL who form.
  • the following steps (i) to (iii) are performed.
  • (i) a step of preparing a cell expressing a fusion gene of MEF2D gene and BCL9 gene (ii) a step of culturing the cell in the presence of the test substance (iii) measuring the number of viable cells, and Step of determining effectiveness
  • a MEF2D-BCL9 fusion gene positive cell is prepared.
  • an ALL cell line for example, NALM-6, BALL-1, CCRF-CEM, Jurkat, CPT-K5
  • MEF2D-BCL9 fusion gene-positive cells for example, a MEF2D-BCL9 fusion gene positive cell.
  • an ALL cell line for example, NALM-6, BALL-1, CCRF-CEM, Jurkat, CPT-K5
  • the prepared cells are cultured in the presence of the test substance.
  • the number of cells to be used is not particularly limited and can be determined in consideration of detection sensitivity, experimental equipment, and the like. For example, 1 ⁇ 10 2 to 1 ⁇ 10 6 cells can be used in one screening operation.
  • the abundance (addition amount) of the test substance in the culture solution can be arbitrarily set, but the addition amount may be set within a range that does not have a fatal effect when normal cells are cultured under the same conditions.
  • a person skilled in the art can set an appropriate addition amount by preliminary experiments.
  • the incubation time is set so that the action / effect of the test substance can be sufficiently evaluated, but is not particularly limited.
  • the culture time can be set within a range of 10 minutes to 1 month.
  • the culture time in the subsequent screening can be set based on the time required for the substance to show the action / effect.
  • organic compounds or inorganic compounds of various molecular sizes can be used as the test substance.
  • organic compounds include nucleic acids, peptides, proteins, lipids (simple lipids, complex lipids (phosphoglycerides, sphingolipids, glycosylglycerides, cerebrosides, etc.), prostaglandins, isoprenoids, terpenes, steroids, polyphenols, catechins, and vitamins.
  • the test substance may be derived from a natural product or synthesized, and in the latter case, an efficient screening system can be constructed by using, for example, a combinatorial synthesis technique.
  • cell extracts, culture supernatants, etc. may be used as test substances, or existing drugs may be used as test substances, by adding two or more kinds of test substances at the same time, You may investigate synergistic action etc.
  • step (iii) following step (ii) the number of viable cells after culturing is measured, and the cell growth inhibitory activity (cytotoxic activity) of the test substance, that is, the effectiveness is determined.
  • the cell growth inhibitory activity cytotoxic activity
  • cells cultured in the presence of the test substance (test group) and cells cultured in the absence of the test substance (control group) are prepared, and the number of viable cells is measured and compared for each group. From the comparison results, the degree to which the cell viability has changed as a result of the presence of the test substance is determined.
  • the number of living cells in the test group is small compared to the control group (cell viability is low), that is, when the test substance shows cell growth inhibitory activity, the test substance exhibits the genetic abnormality of the present invention.
  • the substance (screening result) selected by the screening method of the present invention is a promising candidate (lead compound) as an active ingredient of a medicine for ALL cases having a genetic abnormality of the present invention.
  • the selected substance has a sufficient medicinal effect, it can be used as an active ingredient of a medicine as it is.
  • it can be used as an active ingredient of a medicine after it has been modified by chemical modification to enhance its medicinal effect.
  • the same modification may be applied for the purpose of further increasing the medicinal effect.
  • the present invention further provides a MEF2D-BCL9 fusion gene and a MEF2D-BCL9 fusion protein that define the genetic abnormality of the present invention.
  • the MEF2D-BCL9 fusion gene is caused by a chromosomal inversion in which a breakpoint exists in intron 6 or 7 in the MEF2D gene and a breakpoint exists in exon 8 or intron 9 in the BCL9 gene.
  • the MEF2D-BCL9 fusion protein is an expression product of the fusion gene.
  • MEF2D-BCL9 fusion gene and MEF2D-BCL9 fusion protein can define a new group of ALL, become an index when detecting the group (for example, become a detection target of the test method of the present invention), treatment It is useful in that it can be a target of the above.
  • the genetic abnormality of the present invention causes the onset of ALL.
  • the MEF2D-BCL9 fusion gene contains exons 1 to 6 of the MEF2D gene and exon 10 of the BCL9 gene or a part thereof.
  • a specific example of the sequence of exons 1 to 6 of the MEF2D gene is shown in SEQ ID NO: 11.
  • SEQ ID NO: 12 A specific example of the sequence of exon 10 of the BCL9 gene is shown in SEQ ID NO: 12.
  • MEF2D-BCL9 fusion protein is encoded by the MEF2D-BCL9 fusion gene. Accordingly, the amino acid sequence (SEQ ID NO: 13) corresponding to exons 1 to 6 of the MEF2D gene and the amino acid sequence (SEQ ID NO: 14) corresponding to exon 10 of the BCL9 gene or a part thereof are included.
  • the amino acid sequences of specific examples of the MEF2D-BCL9 fusion protein are shown in SEQ ID NOs: 15-20.
  • the MEF2D-BCL9 fusion gene and MEF2D-BCL9 fusion protein can be prepared in an isolated state, for example, by separating and purifying from a patient having a genetic abnormality of the present invention. Moreover, based on the sequence information disclosed in the present specification, it may be prepared by chemical synthesis, genetic engineering techniques, or the like.
  • the present invention further provides cDNA complementary to mRNA which is a transcription product of the MEF2D-BCL9 fusion gene.
  • the cDNA is particularly useful in that it serves as an index for detecting a new group of ALL (for example, a detection target of the test method of the present invention).
  • the cDNA of the present invention includes the sequence of exons 1 to 6 (SEQ ID NO: 21) of the MEF2D gene and the sequence of exon 10 (SEQ ID NO: 22) of the BCL9 gene or a part thereof. Specific examples of the cDNA of the present invention are shown in SEQ ID NOs: 23 to 28.
  • the cDNA of the present invention can be prepared by a conventional method.
  • various reagents and kits for preparing cDNA are commercially available, and the cDNA of the present invention can be easily prepared by using them.
  • the present invention further provides antibodies that recognize MEF2D-BCL9 fusion proteins.
  • the antibody of the present invention is useful for detecting, for example, MEF2D-BCL9 fusion protein. Therefore, it can be used for the inspection method of the present invention.
  • the antibody of the present invention can be prepared using an immunological technique, a phage display method, a ribosome display method, or the like.
  • Preparation of a polyclonal antibody by an immunological technique can be performed by the following procedure.
  • An antigen (MEF2D-BCL9 fusion protein or a part thereof (including a fusion site)) is prepared and used to immunize animals such as rabbits.
  • An antigen can be obtained by purifying a biological sample.
  • a recombinant antigen can also be used.
  • the recombinant antigen can be expressed, for example, by introducing a gene encoding the MEF2D-BCL9 fusion protein (ie, MEF2D-BCL9 fusion gene) into a suitable host using a vector, and expressing it in the resulting recombinant cell. Can be prepared.
  • an antigen to which a carrier protein is bound may be used.
  • the carrier protein KLH (KeyholeHLimpet) Hemocyanin), BSA (Bovine Serum Albumin), OVA (Ovalbumin) and the like are used.
  • the carbodiimide method, the glutaraldehyde method, the diazo condensation method, the MBS (maleimidobenzoyloxysuccinimide) method, etc. can be used for the coupling
  • MEF2D-BCL9 fusion protein or part thereof is expressed as a fusion protein with GST, ⁇ -galactosidase, maltose-binding protein, histidine (His) tag or the like can also be used.
  • a fusion protein can be easily purified by a general method.
  • Immunization is repeated as necessary, and blood is collected when the antibody titer has sufficiently increased, and serum is obtained by centrifugation or the like. The obtained antiserum is affinity purified to obtain a polyclonal antibody.
  • monoclonal antibodies can be prepared by the following procedure. First, an immunization operation is performed in the same procedure as described above. Immunization is repeated as necessary, and antibody-producing cells are removed from the immunized animal when the antibody titer sufficiently increases. Next, the obtained antibody-producing cells and myeloma cells are fused to obtain a hybridoma. Subsequently, after this hybridoma is monoclonalized, a clone that produces an antibody having high specificity for the target protein (ie, MEF2D-BCL9 fusion protein) is selected. The target antibody can be obtained by purifying the culture medium of the selected clone.
  • the target antibody ie, MEF2D-BCL9 fusion protein
  • the desired antibody can be obtained by growing the hybridoma to a desired number or more, then transplanting it into the abdominal cavity of an animal (for example, a mouse), growing it in ascites, and purifying the ascites.
  • affinity chromatography using protein G, protein A or the like is preferably used.
  • affinity chromatography in which an antigen is immobilized may be used.
  • methods such as ion exchange chromatography, gel filtration chromatography, ammonium sulfate fractionation, and centrifugation can also be used. These methods can be used alone or in any combination.
  • labeling substances that can be used for labeling include fluorescent dyes such as fluorescein, rhodamine, Texas red, oregon green, enzymes such as horseradish peroxidase, microperoxidase, alkaline phosphatase, ⁇ -D-galactosidase, luminol, acridine Chemical or bioluminescent compounds such as dyes, various radioisotopes, biotin.
  • the antibodies of the present invention include antibodies from non-human animals such as mice and rats, chimeric antibodies, humanized antibodies, and human antibodies in which a part of the region has been replaced with those from other animals (including humans).
  • the class of the antibody is not particularly limited.
  • antibodies of the IgG class for example, those belonging to human antibody subclasses IgG1, IgG2, IgG3, and IgG4.
  • MEF2D-BCL9 fusion gene was detected in 4 cases. The detected fusion gene was fused in-frame, suggesting the possibility of producing a functional protein. MEF2D and BCL9 are both located on the long arm of chromosome 1, and the distance between these two genes is about 9 Mb (FIG. 1A). A partial inversion of this site forms a MEF2D-BCL9 fusion gene. This chromosomal abnormality was not detected by G-band staining.
  • RT-PCR Detection of fusion gene mRNA by RT-PCR
  • cDNA extracted from bone marrow containing leukemia cells as a template using ThermoScript TM RT-PCR system (Thermo) was synthesized.
  • RT-PCR was performed using the following primer set corresponding to the sequences of MEF2D and BCL9 and PrimeSTAR (registered trademark) GXL DNA polymerase.
  • the PCR product was subjected to direct sequence analysis using BigDye (registered trademark) Terminater 3.1 (Life Technologies).
  • MEF2D-BCL9 fusion gene detected by RNA sequencing was also confirmed by RT-PCR.
  • the specificity of the RT-PCR method could be confirmed by using healthy subjects as controls.
  • MEF2D-BCL9 in 115 cases of first acute leukemia 100 cases of B progenitor ALL, 4 cases of T cell ALL, 10 cases of acute myeloid leukemia, 1 case of mixed plasma acute leukemia, 1 case of acute mixed leukemia
  • the fusion gene was screened, no new cases of MEF2D-BCL9 fusion gene were detected.
  • the insertion sequence of unknown origin is the junction site (in case 3, MEF2D intron 7 and BCL9 intron 9 are joined via the insertion sequence, and in case 4 MEF2D intron 7 and BCL9 exon 8 are located via the insertion sequence. It was confirmed that this occurred in the bonding).
  • MEF2D-BCL9 fusion gene detected by RNA sequencing was supported by the presence of a breakpoint in the genome. It was also confirmed that this fusion gene could be detected by PCR using the genome as a template.
  • MEF2D-BCL9 in 115 cases of first acute leukemia (100 cases of B progenitor ALL, 4 cases of T cell ALL, 10 cases of acute myeloid leukemia, 1 case of mixed plasma acute leukemia, 1 case of acute mixed leukemia) Although the fusion gene was screened, no new cases of MEF2D-BCL9 fusion gene were detected.
  • MEF2D-BCL9 positive leukemia cells Four cases of MEF2D-BCL9 positive leukemia cells are typical in terms of (i) medium to large blasts, (ii) strong basophil cytoplasm, and (iii) marked vacuolation. It had morphological characteristics different from those of B precursor cells. These findings are similar to those of mature B-cell leukemia, but are differentiated based on the presence of cell surface markers such as CD20 and immunoglobulin, and the presence or absence of an IGH-MYC fusion gene.
  • MEF2D-BCL9 fusion gene useful for predicting the prognosis of ALL and deciding treatment policy.
  • cases are stratified by predicting prognosis using various indicators, and the optimal treatment strategy is determined for each case.
  • the present invention provides a new index useful for stratification of cases, and contributes to optimization of ALL treatment policy and maximization of therapeutic effect.
  • the MEF2D-BCL9 fusion gene is also useful as a target for molecular targeted therapy. Therefore, the present invention is also expected to contribute to the establishment of a new treatment strategy for ALL.
  • SEQ ID NO: 1 description of artificial sequence: forward primer SEQ ID NO: 2: description of artificial sequence: reverse primer SEQ ID NO: 3: description of artificial sequence: forward primer SEQ ID NO: 4: description of artificial sequence: reverse primer SEQ ID NO: 5: artificial sequence Description: forward primer SEQ ID NO: 6: description of artificial sequence: reverse primer SEQ ID NO: 7: description of artificial sequence: forward primer SEQ ID NO: 8: description of artificial sequence: reverse primer SEQ ID NO: 9: description of artificial sequence: forward primer sequence Number 10: description of artificial sequence: reverse primer SEQ ID NO: 21: description of artificial sequence: cDNA of exons 1, 2, 3, 4, 5, 6 of MEF2D gene SEQ ID NO: 22: Description of artificial sequence: cDNA, exon 10 of BCL9 gene, exon 10 cDNA SEQ ID NO: 23: Description of artificial sequence: cDNA encoding MEF2D-BCL9 fusion protein SEQ ID NO: 24: Description of artificial sequence: cDNA encoding MEF2D-BCL9 fusion

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une nouvelle anomalie génétique utile pour la détermination de stratégies thérapeutiques ou la prédiction pronostique de la leucémie aiguë lymphoblastique et contribuant à l'amélioration des résultats thérapeutiques. Une anomalie génétique caractérisée par la formation d'un gène de fusion comprenant le gène MEF2D et le gène BCL9 a été découverte chez des patients atteints de leucémie aiguë lymphoblastique récurrente infantile. Cette anomalie génétique servira de nouvel indicateur lors de la détermination des stratégies thérapeutiques.
PCT/JP2016/088570 2015-12-25 2016-12-22 Nouvelle anomalie génétique liée à la leucémie aiguë lymphoblastique et son utilisation WO2017111129A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017558310A JPWO2017111129A1 (ja) 2015-12-25 2016-12-22 急性リンパ性白血病関連の新規遺伝学的異常及びその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-255179 2015-12-25
JP2015255179 2015-12-25

Publications (1)

Publication Number Publication Date
WO2017111129A1 true WO2017111129A1 (fr) 2017-06-29

Family

ID=59090510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/088570 WO2017111129A1 (fr) 2015-12-25 2016-12-22 Nouvelle anomalie génétique liée à la leucémie aiguë lymphoblastique et son utilisation

Country Status (2)

Country Link
JP (1) JPWO2017111129A1 (fr)
WO (1) WO2017111129A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109593861A (zh) * 2019-02-18 2019-04-09 南方医科大学 不同位点白血病mef2d-bcl9融合基因寡核苷酸的检测方法及检测试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082933A1 (fr) * 2004-02-26 2005-09-09 Bml, Inc. Nouvelle protéine chimère, gène codant celle-ci et moyen d'évaluation d'une leucémie utilisant le gène et la protéine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082933A1 (fr) * 2004-02-26 2005-09-09 Bml, Inc. Nouvelle protéine chimère, gène codant celle-ci et moyen d'évaluation d'une leucémie utilisant le gène et la protéine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
FLAVELL S. ET AL.: "Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection", NEURON, vol. 60, no. 6, 2008, pages 1022 - 1038, XP055600231 *
GU Z. ET AL.: "Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia", NATURE COMMUNICATIONS, vol. 7, no. 13331, 8 November 2016 (2016-11-08), pages 1 - 10, XP055600244 *
GU Z. ET AL.: "Recurrent MEF2D fusions define a new subtype of acute lymphoblastic leukemia associated with older age at diagnosis and poor outcome", PEDIATR . BLOOD CANCER, vol. 63, no. suppl. S3, 27 September 2016 (2016-09-27), pages o-034 - 034 *
LILLJEBJORN H. ET AL.: "RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSFIR fusion responsive to imatinib", LEUKEMIA, vol. 28, 2014, pages 977 - 979, XP055379249, DOI: doi:10.1038/leu.2013.324 *
MANI M. ET AL.: "BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells", CANCER RES., vol. 69, no. 19, 2009, pages 7577 - 7586, XP055600234 *
PRIMA V. ET AL.: "Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19) (q23;p13. 3) in acute lymphoblastic leukemia", LEUKEMIA, vol. 19, no. 5, 2005, pages 806 - 813 *
PRIMA V. ET AL.: "Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia", LEUKEMIA, vol. 21, no. 12, 1 December 2007 (2007-12-01), pages 2470 - 2475, XP055379245, DOI: doi:10.1038/sj.leu.2404962 *
SUZUKI K. ET AL.: "MEF2D-BCL9 fusion gene is associated with high-risk acute B- cell precursor lymphoblastic leukemia in adolescents", JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 28, 1 October 2016 (2016-10-01), pages 3451 - 3459, XP055600241 *
YUKI Y. ET AL.: "Identification of a novel fusion gene in a pre-B acute lymphoblastic leukemia with t(1;19)(q23;p13)", CANCER SCI., vol. 95, no. 6, 2004, pages 503 - 507, XP055600239 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109593861A (zh) * 2019-02-18 2019-04-09 南方医科大学 不同位点白血病mef2d-bcl9融合基因寡核苷酸的检测方法及检测试剂盒

Also Published As

Publication number Publication date
JPWO2017111129A1 (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
de la Morena Clinical phenotypes of hyper-IgM syndromes
US20220195529A1 (en) Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
EP3064591B1 (fr) Profilage de microréseau de phase de la réponse humorale à une maladie
JP6404208B2 (ja) 特発性肺線維症の予後予測、診断および処置の方法
CA3100345A1 (fr) Adn acellulaire pour evaluer et/ou traiter le cancer
EP3601615A1 (fr) Profilage de stabilité génomique
US20130096021A1 (en) Recurrent gene fusions in breast cancer
JP2008546387A (ja) 癌を処置および診断するための組成物および方法
US11262358B2 (en) Infiltrating immune cell proportions predict anti-TNF response in colon biopsies
CA2854255C (fr) Mutations des proteines histones associees aux troubles proliferatifs of
US20160272720A1 (en) Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes
US11254988B2 (en) Somatic mutations in ATRX in brain cancer
US20120052079A1 (en) Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
JP2010178650A (ja) 固形癌の再発予測のための試験方法および再発予防剤
CA2934878A1 (fr) Reorganisations genomiques associees a un cancer de la prostate, et leurs procedes d'utilisation
WO2020141199A1 (fr) Méthodes et compositions pharmaceutiques pour améliorer les réponses immunitaires dépendantes des lymphocytes t cd8+ chez des sujets souffrant d'un cancer
JP2014531020A (ja) 癌のマーカーとしてのｂｉｎ１の発現
WO2017111129A1 (fr) Nouvelle anomalie génétique liée à la leucémie aiguë lymphoblastique et son utilisation
US8597883B2 (en) Biomarkers for cancer-related fatigue and use thereof
US20220325346A1 (en) Use of snca-mediated genes for diagnosis and treatment of parkinson's disease
CN116411080B (zh) 一种区分冷、热肿瘤的标志物
KR102202120B1 (ko) 알츠하이머 질환의 진단 또는 치료를 위한 Ｕｂｅ２ｈ의 용도
US20220298580A1 (en) Immune signatures predictive of response to pd-1 blockade in richter's transformation
US20040138161A1 (en) Methods of modulating proliferative conditions
Kee Investigating lymphoid-like structures in the pathogenesis of Multiple Sclerosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16879015

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017558310

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16879015

Country of ref document: EP

Kind code of ref document: A1